Abbott Laboratories (NYSE:ABT) Chairman Miles D. White sold 276,886 shares of the firm’s stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $54.41, for a total transaction of $15,065,367.26. Following the transaction, the chairman now directly owns 3,677,913 shares of the company’s stock, valued at $200,115,246.33. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Abbott Laboratories (ABT) traded down $0.05 during trading on Friday, reaching $54.64. 5,030,945 shares of the company were exchanged, compared to its average volume of 5,121,944. Abbott Laboratories has a 1 year low of $37.90 and a 1 year high of $56.69. The firm has a market cap of $95,193.46, a PE ratio of 22.69, a P/E/G ratio of 2.05 and a beta of 1.06. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The firm had revenue of $6.83 billion for the quarter, compared to analysts’ expectations of $6.72 billion. During the same quarter last year, the company earned $0.59 EPS. The firm’s revenue for the quarter was up 28.8% compared to the same quarter last year. sell-side analysts predict that Abbott Laboratories will post 2.49 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 15th. Investors of record on Friday, October 13th were paid a $0.265 dividend. The ex-dividend date of this dividend was Thursday, October 12th. This represents a $1.06 dividend on an annualized basis and a yield of 1.94%. Abbott Laboratories’s dividend payout ratio is currently 83.47%.

A number of institutional investors have recently added to or reduced their stakes in the stock. Villere ST Denis J & Co. LLC boosted its stake in Abbott Laboratories by 2.3% during the 2nd quarter. Villere ST Denis J & Co. LLC now owns 268,200 shares of the healthcare product maker’s stock worth $13,037,000 after purchasing an additional 5,950 shares during the last quarter. Private Bank & Trust Co. boosted its stake in Abbott Laboratories by 12.3% during the 2nd quarter. Private Bank & Trust Co. now owns 30,322 shares of the healthcare product maker’s stock worth $1,473,000 after purchasing an additional 3,330 shares during the last quarter. Gratus Capital LLC boosted its stake in Abbott Laboratories by 0.9% during the 2nd quarter. Gratus Capital LLC now owns 205,067 shares of the healthcare product maker’s stock worth $9,968,000 after purchasing an additional 1,869 shares during the last quarter. Comerica Securities Inc. acquired a new stake in Abbott Laboratories during the 1st quarter worth $2,833,000. Finally, AQR Capital Management LLC boosted its stake in Abbott Laboratories by 264.8% during the 1st quarter. AQR Capital Management LLC now owns 634,391 shares of the healthcare product maker’s stock worth $28,173,000 after purchasing an additional 460,477 shares during the last quarter. 71.01% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have issued reports on the stock. ValuEngine lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price objective on the stock in a research note on Tuesday, October 31st. Barclays reaffirmed an “overweight” rating on shares of Abbott Laboratories in a research note on Thursday, October 19th. Citigroup reaffirmed a “neutral” rating on shares of Abbott Laboratories in a research note on Thursday, October 19th. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Abbott Laboratories in a research note on Thursday, October 19th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Abbott Laboratories presently has an average rating of “Buy” and a consensus price target of $56.81.

COPYRIGHT VIOLATION WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.watchlistnews.com/abbott-laboratories-abt-chairman-miles-d-white-sells-276886-shares/1753743.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.